With interest we read the article by Benny and Khadilkar about a literature review focusing on neuromuscular abnormalities in patients infected with SARS-CoV-2 causing COVID-19.\(^1\) It was concluded that neuromuscular involvement in COVID-19 patients is relatively uncommon.\(^1\)

We have the following comments and concerns.

With regard to polyradiculitis [Guillain-Barre syndrome (GBS)] the authors mention that only a single case has been reported.\(^1\) This is by far not the case as shown in a recent review of 24 patients with SARS-CoV-2 associated GBS.\(^2\) In a more recent review even 62 COVID-19 patients with GBS were identified. Meanwhile, at least 220 post-COVID-19 GBS cases have been reported [Finsterer, submitted]. The 24 patients included in the first review originated from Italy (n = 9), Spain (n = 5), USA (n = 2), France (n = 2), Iran (n = 1), Morocco (n = 1), Germany (n = 1), Switzerland (n = 1), India (n = 1), and China (1). Age ranged from 20 to 76 years. There was a male preponderance. The latency between the onset of COVID-19 and onset of GBS ranged from 3 to 23 days, with a mean latency of 10 days. Fourteen patients were classified as acute inflammatory demyelinating polyneuropathy (AIDP), 4 with acute motor axonal neuropathy (AMAN), 3 with Miller

**Neuromuscular Involvement in COVID-19 Patients**

With interest we read the article by Benny and Khadilkar about a literature review focusing on neuromuscular abnormalities in patients infected with SARS-CoV-2 causing COVID-19.\(^1\) It was concluded that neuromuscular involvement in COVID-19 patients is relatively uncommon.\(^1\)

We have the following comments and concerns.

With regard to polyradiculitis [Guillain-Barre syndrome (GBS)] the authors mention that only a single case has been reported.\(^1\) This is by far not the case as shown in a recent review of 24 patients with SARS-CoV-2 associated GBS.\(^2\) In a more recent review even 62 COVID-19 patients with GBS were identified. Meanwhile, at least 220 post-COVID-19 GBS cases have been reported [Finsterer, submitted]. The 24 patients included in the first review originated from Italy (n = 9), Spain (n = 5), USA (n = 2), France (n = 2), Iran (n = 1), Morocco (n = 1), Germany (n = 1), Switzerland (n = 1), India (n = 1), and China (1). Age ranged from 20 to 76 years. There was a male preponderance. The latency between the onset of COVID-19 and onset of GBS ranged from 3 to 23 days, with a mean latency of 10 days. Fourteen patients were classified as acute inflammatory demyelinating polyneuropathy (AIDP), 4 with acute motor axonal neuropathy (AMAN), 3 with Miller
Letters to the Editor

Fisher syndrome (MFS), and 2 with acute motor and sensory axonal neuropathy (AMSAN). In none of the 15 patients undergoing CSF investigations was the virus detected in the CSF. Immunoglobulins were given to 21 patients. Steroids were applied to 1 patient. Seven patients required mechanical ventilation. Recovery was achieved in 13 patients. The outcome was poor in 6 patients and fatal in 2.

With regard to hypogeusia and hyposmia, it is currently undetermined whether these early manifestations of the infection have to be classified as a central nervous system (CNS) manifestation or as a peripheral nervous system (PNS) manifestation. In several recent reviews about the topic, various different pathomechanisms were discussed. Hypogeusia or hyposmia was attributed to meningitis/encephalitis, cranial nerve affection, stomatitis/rhinitis, an immune reaction, to side effects of certain drugs, or to direct contact of the virus with taste buds or olfactory receptors.

Concerning myositis as a manifestation of COVID-19, there is one report about a single patient experiencing myositis from the viral infection. Myositis in this particular patient was confirmed by muscle magnetic resonance imaging (MRI). In a retrospective study from China of 214 COVID-19 patients, the frequency of myalgia together with elevated creatine-kinase was 10.7%. Generally, the frequency of isolated myalgia in COVID-19 patients ranges from 11% to 50%. In an autopsy study of 10 patients experiencing fatal COVID-19 infection, myositis was detected in 60% of the patients. In patients with autoimmune dermatomyositis antibodies against epitopes with high sequence identity to SARS-CoV-2 were detected.

Missing in this review is a report about a COVID-19 patient in whom the viral infection triggered the development of myasthenia.

Plexopathy or plexitis has, according to our knowledge, not been reported in association with COVID-19 so far.

The authors speculate that the virus can enter the PNS but do not specify the pathway or mechanism by which the agent attacks the PNS. We should know how the authors explain the involvement of the PNS in COVID-19.

Overall, this interesting review about the involvement of the PNS in COVID-19 has a number of limitations as outlined above, which need to be addressed to modify the conclusions. The study may profit from a systematic and thorough search for PNS affection in COVID-19.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Josef Finsterer
Krankenanstalt Rudolfstiftung, Messerli Institute, Vienna, Austria

Address for correspondence: Dr. Josef Finsterer, Krankenanstalt Rudolfstiftung, Messerli Institute, Postfach 20, Vienna - 1180, Austria.
E-mail: fifigs1@yahoo.de

References
1. Benny R, Khadilkar SV. COVID 19: Neuromuscular manifestations. Ann Indian Acad Neurol 2020;23(suppl 1):S40–2.
2. Finsterer J, Scorza FA, Ghosh R. COVID-19 polyradiculitis in 24 patients without SARS-CoV-2 in the cerebro-spinal fluid. J Med Virol 2020;10.1002/jmv. 26212. doi: 10.1002/jmv. 26212. Online ahead of print
3. Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV-2 infected patients. J Med Virol 2020;10.1002/jmv.25903. doi: 10.1002/jmv.25903. Online ahead of print.
4. Lee JM, Lee SJ. Olfactory and gustatory dysfunction in a COVID-19 patient with ankylosing spondylitis treated with etanercept: Case report. J Korean Med Sci 2020;35:e201.
5. Lechien JR, Cabaraux P, Chiesa-Estomba CM, Khalife M, Plzak J, Hars S, et al. Psychophysical olfactory tests and detection of COVID-19 in patients with sudden onset olfactory dysfunction: A prospective study. Ear Nose Throat J 2020;145561320929169. doi: 10.1177/0145561320929169
6. Beydon M, Chevalier K, Al Tabaa O, Hamroun S, Delettre A-S, Thomas M, et al. Myositis as a manifestation of SARS-CoV-2. Ann Rheum Dis 2020;annrheumdis-2020-217573. doi: 10.1136/ annrheumdis-2020-217573. Online ahead of print.
7. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with Coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020;77:1-9.
8. Nunes Duarte-Neto A, de Almeida Monteiro RA, da Silva LFF, Malheiro DMAC, de Oliveira EP, Filho JT, et al. Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy. Histopathology 2020;10.1111/his.14160. doi: 10.1111/his.14160. Online ahead of print.
9. Megremis S, Walker TDJ, He X, Ollier WER, Chinoy H, Hampson L, et al. Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis. Ann Rheum Dis 2020;annrheumdis-2020-217522. doi: 10.1136/ annrheumdis-2020-217522. Online ahead of print.
10. Delfy F, Syed MJ, Lisak RP, Zutshi D. Myasthenic crisis in COVID-19. J Neurol Sci 2020;414:116888.

Submitted: 06-Jun-2020 Accepted: 14-Jun-2020
Published: 24-Mar-2021

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: 10.4103/aiian.AIAN_565_20